Keywords: epo, boosts, dragon, pharma, revenues, pharmaceutical, canada

EPO boosts Dragon Pharma revenues

Article | 09 June 2003

Dragon Pharmaceutical of Canada has posted first-quarter 2003 revenues of $664,322 from the sale of recombinant human erythropoietin, which is currently approved ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing